Skip to main content
Clinical Trials/NCT07411443
NCT07411443RecruitingNot Applicable

Population-based Breast Cancer Screening Study Using AI-Assisted Imaging Technology

Fudan University1 site in 1 country16,000 target enrollmentStarted: January 1, 2025Last updated:
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Enrollment
16,000
Locations
1
Primary Endpoint
The incidence of early-stage breast cancer over a one-year follow-up period, compared between women who underwent AI-assisted screening and those with routine screening

Study Overview

Brief Summary

Artificial Intelligence (AI)-assisted imaging technologies (including AI-assisted breast ultrasound and AI-assisted mammography) can effectively improve the accuracy and efficiency of breast imaging examinations, but their application in large-scale population-based breast cancer screening remains very limited.

This project aims to improve the effectiveness and feasibility of breast cancer screening by addressing the core issues and bottlenecks in population-based breast cancer screening. We will conduct a prospective cluster-controlled screening trial in the general population, with district-based cluster grouping. The intervention group will undergo combined screening using AI-assisted ultrasound plus AI-assisted mammography, while the control group will receive conventional screening: breast ultrasound for initial screening and mammography for secondary screening.

Based on population screening practices, we will evaluate the effectiveness of AI-assisted imaging diagnostic technology in various technical aspects of actual screening and perform cost-effectiveness analyses. This study will investigate the application of AI-assisted breast imaging technology in population-based breast cancer screening, providing scientific evidence for the large-scale implementation of AI-assisted imaging technologies. Furthermore, by combining population screening practices with model simulations, we will explore multi-dimensional breast cancer screening strategies to optimize screening approaches and technologies for the Chinese population.

Study Design

Study Type
Interventional
Allocation
Non Randomized
Intervention Model
Parallel
Primary Purpose
Screening
Masking
None

Eligibility Criteria

Ages
35 Years to 69 Years (Adult, Older Adult)
Sex
Female
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • women aged 35 to 69 years, who were attending the "Two Cancers (Breast and Cervical Cancer) Screening" project, and had no history of breast cancer, including in-situ cancer, or any other cancers in the previous five years.

Exclusion Criteria

  • have serious cardiopulmonary insufficiency, liver or kidney insufficiency, or other systemic diseases, and a life expectancy of less than five years

Arms & Interventions

AI-assisted screening

Experimental

Intervention: AI-assisted screening (Device)

Routine screening

No Intervention

Outcomes

Primary Outcomes

The incidence of early-stage breast cancer over a one-year follow-up period, compared between women who underwent AI-assisted screening and those with routine screening

Time Frame: From enrollment to 1-year after the end of screening

Early-stage breast cancer was defined as cancer confined to the breast (local) or to the breast and regional lymph nodes (locoregional). Specifically, it referred to tumors \<2 cm in diameter, with no ipsilateral axillary lymph node involvement and no distant metastasis. According to the American Joint Committee on Cancer (AJCC) TNM staging system (8th edition) and the Chinese Guideline for Breast Cancer Screening and Early Diagnosis and Treatment (2021, Beijing), early-stage breast cancer encompassed stage 0 (including ductal carcinoma in situ and lobular carcinoma in situ), stage I, and stage II.

The detection rate of suspicious breast lesions (including masses and calcifications) over a one-year follow-up period, compared between women who underwent AI-assisted ultrasound combined with AI-assisted mammography and those who received routine scree

Time Frame: From enrollment to 1-year after the end of screening

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Ying Zheng

professor

Fudan University

Study Sites (1)

Loading locations...

Similar Trials